Protara Therapeutics Inc expected to post a loss of 94  cents a share - Earnings Preview

Protara Therapeutics

07/03/2022 13:49

* Protara Therapeutics Inc  TARA.OQ   TARA.O  is expected
to show
no change in quarterly revenue when it reports  results on March
9 (estimated). 
    * ​Refinitiv's mean analyst estimate for Protara
Therapeutics Inc
is for a loss of 94 cents per share. For the same quarter last
year, the company reported a loss of 44 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protara
Therapeutics Inc is $39​, about 88.9% above​ its last closing
price of $4.33. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -1.11       -1.01      -0.96     Beat    5
 Jun. 30 2021  -1.10       -1.05      -1.14     Missed  -8.3
 Mar. 31 2021  -0.73       -0.73      -1.20     Missed  -65.1​
 Dec. 31 2020  -0.52       -0.54      -0.44     Beat    19
 ​​Sep.        -0.65       -0.62      -1.26     Missed  -101.6
 30 2020                                                
 Jun. 30 2020              -0.46      -1.22     Missed  -165.2
                                                        ​
 Mar. 31 2020  -0.41       -0.41      -1.81     Missed  -341.5
 Dec. 31 2019  -0.71       -0.71      -2.55     Missed  -259.2
 This summary was machine generated March 7 at 13:49 GMT.  All
figures in US dollars  unless otherwise stated